Nilotinib as frontline therapy for patients with newly diagnosed Ph chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd (Q83978299)

From Wikidata

Jump to navigation Jump to search

scientific article published on April 27, 2011

Language	Label	Description	Also known as
English	Nilotinib as frontline therapy for patients with newly diagnosed Ph chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd	scientific article published on April 27, 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523338 AND SRC:MED&resulttype=core&format=json

29 January 2020

Nilotinib as frontline therapy for patients with newly diagnosed Ph chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523338 AND SRC:MED&resulttype=core&format=json

29 January 2020

myeloid leukemia

1 reference

based on heuristic

inferred from title

chronic myeloid leukemia

1 reference

based on heuristic

inferred from title

Chiaki Nakaseko

5

object named as

Chiaki Nakaseko

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523338 AND SRC:MED&resulttype=core&format=json

29 January 2020

Masamitsu Yanada

12

object named as

Masamitsu Yanada

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21523338

30 November 2024

author name string

Hirohisa Nakamae

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523338 AND SRC:MED&resulttype=core&format=json

29 January 2020

Hirohiko Shibayama

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523338 AND SRC:MED&resulttype=core&format=json

29 January 2020

Mineo Kurokawa

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523338 AND SRC:MED&resulttype=core&format=json

29 January 2020

Tetsuya Fukuda

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523338 AND SRC:MED&resulttype=core&format=json

29 January 2020

Yoshinobu Kanda

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523338 AND SRC:MED&resulttype=core&format=json

29 January 2020

Tadashi Nagai

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523338 AND SRC:MED&resulttype=core&format=json

29 January 2020

Kazunori Ohnishi

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523338 AND SRC:MED&resulttype=core&format=json

29 January 2020

Yasuhiro Maeda

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523338 AND SRC:MED&resulttype=core&format=json

29 January 2020

Akira Matsuda

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523338 AND SRC:MED&resulttype=core&format=json

29 January 2020

Taro Amagasaki

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523338 AND SRC:MED&resulttype=core&format=json

29 January 2020

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21523338

30 November 2024

publication date

27 April 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523338 AND SRC:MED&resulttype=core&format=json

29 January 2020

full work available at URL

http://link.springer.com/content/pdf/10.1007/s12185-011-0841-8.pdf

Portable Document Format

1 reference

10.1007/S12185-011-0841-8

https://api.crossref.org/works/10.1007/S12185-011-0841-8

30 November 2024

http://link.springer.com/article/10.1007/s12185-011-0841-8/fulltext.html

1 reference

10.1007/S12185-011-0841-8

https://api.crossref.org/works/10.1007/S12185-011-0841-8

30 November 2024

http://link.springer.com/content/pdf/10.1007/s12185-011-0841-8

1 reference

10.1007/S12185-011-0841-8

https://api.crossref.org/works/10.1007/S12185-011-0841-8

30 November 2024

International Journal of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523338 AND SRC:MED&resulttype=core&format=json

29 January 2020

93

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523338 AND SRC:MED&resulttype=core&format=json

29 January 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523338 AND SRC:MED&resulttype=core&format=json

29 January 2020

624-632

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21523338 AND SRC:MED&resulttype=core&format=json

29 January 2020

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

1 reference

https://pubmed.ncbi.nlm.nih.gov/21523338

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nilotinib for the frontline treatment of Ph( ) chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/21523338

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/21523338

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib

1 reference

https://pubmed.ncbi.nlm.nih.gov/21523338

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase

1 reference

https://pubmed.ncbi.nlm.nih.gov/21523338

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Staging and prognosis in chronic myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/21523338

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph CML or relapsed/refractory Ph ALL.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21523338

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Imatinib for newly diagnosed chronic-phase chronic myeloid leukemia: results of a prospective study in Japan

1 reference

https://pubmed.ncbi.nlm.nih.gov/21523338

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

1 reference

https://pubmed.ncbi.nlm.nih.gov/21523338

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

1 reference

https://pubmed.ncbi.nlm.nih.gov/21523338

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/21523338

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

https://pubmed.ncbi.nlm.nih.gov/21523338

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Harmonization of molecular monitoring of CML therapy in Europe

1 reference

https://pubmed.ncbi.nlm.nih.gov/21523338

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21523338

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Unstable Alpha Hemoglobin Stabilizing Protein as a Cause of Thalassemia: Proof of Concept.

1

1 reference

10.1007/S12185-011-0841-8

https://api.crossref.org/works/10.1007/S12185-011-0841-8

30 November 2024

Journal of Clinical Oncology

6

28

487s

author name string

RA Larson

publication date

2010

1 reference

10.1007/S12185-011-0841-8

https://api.crossref.org/works/10.1007/S12185-011-0841-8

30 November 2024

7

95

340

author name string

M O’Dwyer

publication date

2010

1 reference

10.1007/S12185-011-0841-8

https://api.crossref.org/works/10.1007/S12185-011-0841-8

30 November 2024

Journal of Clinical Oncology

8

28

490s

author name string

G Rosti

publication date

2010

1 reference

10.1007/S12185-011-0841-8

https://api.crossref.org/works/10.1007/S12185-011-0841-8

30 November 2024

CD14 hla-DR-/Lo Myeloid-Derived Suppressor Cells Express Immunosuppressive B7-H Family Members and Are Depleted Following Taxane-Based Chemotherapy in Melanoma.

9

1 reference

10.1007/S12185-011-0841-8

https://api.crossref.org/works/10.1007/S12185-011-0841-8

30 November 2024

Harmonization of Molecular Monitoring of CML Therapy in Europe – Perspective of Widespread Competence in BCR-ABL Quantification.

15

1 reference

10.1007/S12185-011-0841-8

https://api.crossref.org/works/10.1007/S12185-011-0841-8

30 November 2024

Unstable Alpha Hemoglobin Stabilizing Protein as a Cause of Thalassemia: Proof of Concept.

19

1 reference

10.1007/S12185-011-0841-8

https://api.crossref.org/works/10.1007/S12185-011-0841-8

30 November 2024

Journal of Clinical Oncology

20

28

500s

author name string

TP Hughes

publication date

2010

1 reference

10.1007/S12185-011-0841-8

https://api.crossref.org/works/10.1007/S12185-011-0841-8

30 November 2024

24

94

255

author name string

F Nicolini

publication date

2009

1 reference

10.1007/S12185-011-0841-8

https://api.crossref.org/works/10.1007/S12185-011-0841-8

30 November 2024

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q83978299&oldid=2282945526"